Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 164

1.

How dry is "OAB-dry"? Perspectives from patients and physician experts.

Anger JT, Le TX, Nissim HA, Rogo-Gupta L, Rashid R, Behniwal A, Smith AL, Litwin MS, Rodriguez LV, Wein AJ, Maliski SL.

J Urol. 2012 Nov;188(5):1811-5. doi: 10.1016/j.juro.2012.07.044. Epub 2012 Sep 19.

2.

Women's experience with severe overactive bladder symptoms and treatment: insight revealed from patient focus groups.

Anger JT, Nissim HA, Le TX, Smith AL, Lee U, Sarkisian C, Litwin MS, Raz S, Rodriguez LV, Maliski SL.

Neurourol Urodyn. 2011 Sep;30(7):1295-9. doi: 10.1002/nau.21004. Epub 2011 Apr 28.

3.

Urgency is the core symptom of female overactive bladder syndrome, as demonstrated by a statistical analysis.

Hung MJ, Ho ES, Shen PS, Sun MJ, Lin AT, Chen GD; Taiwan OAB Club.

J Urol. 2006 Aug;176(2):636-40.

PMID:
16813910
4.

Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial.

Chapple C, Schneider T, Haab F, Sun F, Whelan L, Scholfield D, Dragon E, Mangan E.

BJU Int. 2014 Sep;114(3):418-26. doi: 10.1111/bju.12678. Epub 2014 Jul 1.

5.

Misconceptions and miscommunication among aging women with overactive bladder symptoms.

Smith AL, Nissim HA, Le TX, Khan A, Maliski SL, Litwin MS, Sarkisian CA, Raz S, Rodríguez LV, Anger JT.

Urology. 2011 Jan;77(1):55-9. doi: 10.1016/j.urology.2010.07.460. Epub 2010 Oct 23.

6.

Correlation between psychological stress levels and the severity of overactive bladder symptoms.

Lai H, Gardner V, Vetter J, Andriole GL.

BMC Urol. 2015 Mar 8;15:14. doi: 10.1186/s12894-015-0009-6.

7.

Analysis of bladder diary with urinary perception to assess overactive bladder symptoms in community-dwelling women.

Honjo H, Kawauchi A, Ukimura O, Nakao M, Kitakoji H, Miki T.

Neurourol Urodyn. 2009;28(8):982-5. doi: 10.1002/nau.20704.

PMID:
19267392
8.

Defining and managing overactive bladder: disagreement among the experts.

Lee UJ, Scott VC, Rashid R, Behniwal A, Wein AJ, Maliski SL, Anger JT.

Urology. 2013 Feb;81(2):257-62. doi: 10.1016/j.urology.2012.09.028.

9.

Urgency severity scale could predict urodynamic detrusor overactivity in patients with overactive bladder syndrome.

Chung SD, Liao CH, Chen YC, Kuo HC.

Neurourol Urodyn. 2011 Sep;30(7):1300-4. doi: 10.1002/nau.21057. Epub 2011 May 10.

PMID:
21560153
10.

[Epidemiology and pathophysiology of overactive bladder].

Schumacher S.

Urologe A. 2006 Jul;45(7):822-5. Review. German.

PMID:
16758202
11.

Overactive bladder in Taiwanese women: re-analysis of epidemiological database of community from 1999 to 2001.

Chen YC, Ng SC, Chen SL, Huang YH, Hu SW, Chen GD.

Neurourol Urodyn. 2012 Jan;31(1):56-9. doi: 10.1002/nau.21190. Epub 2011 Aug 8. Review.

PMID:
21826728
12.

Assessment of treatment-seeking behavior and healthcare utilization in an international cohort of subjects with overactive bladder.

Jimenez-Cidre M, Costa P, Ng-Mak D, Sahai A, Degboe A, Smith CP, Tsai K, Herschorn S.

Curr Med Res Opin. 2014 Aug;30(8):1557-64. doi: 10.1185/03007995.2014.918028. Epub 2014 May 12.

PMID:
24762033
13.

The translation and validation of Chinese overactive bladder symptom score for assessing overactive bladder syndrome and response to solifenacin treatment.

Chou EC, Hung MJ, Yen TW, Chuang YC, Meng E, Huang ST, Kuo HC.

J Formos Med Assoc. 2014 Aug;113(8):506-12. doi: 10.1016/j.jfma.2012.07.044. Epub 2012 Oct 16.

14.

Which anticholinergic drug for overactive bladder symptoms in adults.

Madhuvrata P, Cody JD, Ellis G, Herbison GP, Hay-Smith EJ.

Cochrane Database Syst Rev. 2012 Jan 18;1:CD005429. doi: 10.1002/14651858.CD005429.pub2. Review.

PMID:
22258963
15.

The overactive bladder-symptom composite score: a composite symptom score of toilet voids, urgency severity and urge urinary incontinence in patients with overactive bladder.

Zinner N, Harnett M, Sabounjian L, Sandage B Jr, Dmochowski R, Staskin D.

J Urol. 2005 May;173(5):1639-43. Erratum in: J Urol. 2005 Aug;174(2):796.

PMID:
15821526
16.

Urinary incontinence and overactive bladder in patients with heart failure.

Palmer MH, Hardin SR, Behrend C, Collins SK, Madigan CK, Carlson JR.

J Urol. 2009 Jul;182(1):196-202. doi: 10.1016/j.juro.2009.02.115. Epub 2009 May 17.

PMID:
19447424
17.

[Prevalence of overactive bladder in Spain: a population-based study].

Castro D, Espuña M, Prieto M, Badia X.

Arch Esp Urol. 2005 Mar;58(2):131-8. Spanish.

PMID:
15847270
18.

Validation of a 3-item OAB awareness tool.

Coyne KS, Margolis MK, Bavendam T, Roberts R, Elinoff V.

Int J Clin Pract. 2011 Feb;65(2):219-24. doi: 10.1111/j.1742-1241.2010.02561.x.

PMID:
21235701
19.

OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial.

Nitti VW, Dmochowski R, Herschorn S, Sand P, Thompson C, Nardo C, Yan X, Haag-Molkenteller C; EMBARK Study Group.

J Urol. 2013 Jun;189(6):2186-93. doi: 10.1016/j.juro.2012.12.022. Epub 2012 Dec 14.

PMID:
23246476
20.

Reduced perception of urgency in treatment of overactive bladder with extended-release tolterodine.

Freeman R, Hill S, Millard R, Slack M, Sutherst J; Tolterodine Study Group.

Obstet Gynecol. 2003 Sep;102(3):605-11.

PMID:
12962951

Supplemental Content

Support Center